First Real-World Insights into Belimumab Use and Outcomes in Routine Clinical Care of Systemic Lupus Erythematosus in Germany: Results from the OBSErve Germany Study

OBSErve Germany was the first observational study of belimumab as add-on treatment for systemic lupus erythematosus (SLE) in routine clinical care in Germany, retrospectively collecting data from 102 SLE patients, 6 months before and after belimumab initiation. Most patients had moderate or severe S...

Descripción completa

Detalles Bibliográficos
Autores principales: Schwarting, Andreas, Schroeder, Johann O., Alexander, Tobias, Schmalzing, Marc, Fiehn, Christoph, Specker, Christof, Perna, Alessandra, Cholmakow-Bodechtel, Constanze, Koscielny, Volker B., Carnarius, Heike
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2016
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5127971/
https://www.ncbi.nlm.nih.gov/pubmed/27804088
http://dx.doi.org/10.1007/s40744-016-0047-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5127971/
https://www.ncbi.nlm.nih.gov/pubmed/27804088
http://dx.doi.org/10.1007/s40744-016-0047-x

Ejemplares similares